中文

瑞普生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥0.83B+0.5%
Gross profit¥0.33B
Operating income¥0.13B
Net income¥0.12B-2.2%
Gross margin39.7%Net margin 14.2%
Revenue Q/Q-3.3%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.50B60.3%
R&D¥0.05B5.5%
SG&A¥0.14B17.5%
Tax & other¥0.01B1.4%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

经纬辉开阳谷华泰ST亚光*ST聆达锐奇股份银河磁体锦富技术泰胜风能新国都英唐智控青松股份华策影视

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies